ライフサイエンスコーパス: cold ischemia time

1 nsitized patients in spite of similar length cold ischemia time.

2 prevalent in cadaveric allografts with long cold ischemia time.

3 variables included age, weight, gender, and cold ischemia time.

4 ps in terms of recipient sex, race, age, and cold ischemia time.

5 th University of Wisconsin solution and 6-hr cold ischemia time.

6 al donors (n = 14) matched for age, BMI, and cold ischemia time.

7 ntigen mismatch, pretransplant dialysis, and cold ischemia time.

8 g donor type, HLA mismatches, donor age, and cold ischemia time.

9 ale donor, PRA as a continuous variable, and cold ischemia time.

10 n of CD14 mRNA correlated with the length of cold ischemia time.

11 diate-term graft survival despite increasing cold ischemia time.

12 l with donor BMI >30 (P=0.06) and increasing cold-ischemia time.

13 seen in grafts from older donors and longer cold ischemia times.

14 om older, more mismatched donors with longer cold ischemia times.

15 nce of delayed graft function (38% vs. 26%), cold ischemia times (12.9 vs. 13.5 hr), and graft surviv

16 of HAT was 8 out of 73 transplants (11%).The cold ischemia time (14.3 +/- 3.03 hr) in this group was

17 wait-time (571 vs. 471 days, P<0.01), longer cold ischemia time (22 vs. 20 hr, P<0.01), and donor and

18 ed with recipients of kidneys with a shorter cold ischemia time (3.2%).

19 We found that a prolonged cold ischemia time (6-12 hr) alone did not induce IE.

20 age Liver Disease score was 15 (IQR, 11-21); cold ischemia time, 8.0 hours (IQR, 6.4-9.7 hours); MEAF

21 levels of panel-reactive antibodies, shorter cold ischemia times, a lower incidence of delayed graft

22 Increased donor age and cold ischemia time additionally decreased graft survival

23 ed with DDK with non-DGF after adjusting for cold ischemia time (alpha=0.001).

24 ations of kidneys with less than 12 hours of cold ischemia time and 74,997 dollars for those with mor

25 ible donors, and is associated with a longer cold ischemia time and a potentially higher rejection ra

26 risk factors for reduced graft survival are cold ischemia time and donor age.

27 uld be reallocated without delay to minimize cold ischemia time and maximize the utility of the graft

28 with intrahepatic strictures, and prolonged cold ischemia time and rejection were associated with st

29 When results were adjusted for cold ischemia time and sex, iNO significantly decreased

30 Non-treated allogeneic grafts without cold ischemia time and syngeneic grafts did not develop

31 The short tolerable cold ischemia time and the importance of other risk fact

32 prospective cross-match as a means to reduce cold ischemia time and the incidence of delayed graft fu

33 Prolonged cold ischemia time and use of a whole graft with recipie

34 nal allocation variance designed to minimize cold ischemia times and encourage adoption of DCD protoc

35 ave focused on graft damage due to prolonged cold ischemia times and rewarming during the long benchi

36 early allograft dysfunction with increasing cold ischemia times and should be transplanted within 12

37 iated with early transplant stressors (e.g., cold ischemia time) and donor aging.

38 antibody titer, extent of HLA matching, and cold-ischemia time), and post-transplantation variables

39 ly significant factors such as HLA mismatch, cold ischemia time, and African-American or diabetic rec

40 ominal sepsis) and donor factors (donor age, cold ischemia time, and donor cytomegalovirus status), m

41 , human leukocyte antigen-B and DR mismatch, cold ischemia time, and double or en bloc transplant.

42 ransplanted, increment of insulin secretion, cold ischemia time, and exocrine tissue volume transplan

43 size, age of donor kidney, damage caused by cold ischemia time, and mode of donor death all had subs

44 t to include both nonimmunologic (donor age, cold ischemia time, and recipient race) and immunologic

45 RA), recipient and donor race and donor age, cold ischemia time, and the pretransplantation use of ei

46 ats that received a liver graft with a 16-hr cold ischemia time, and the survival rate was 83% after

47 he effects of this system on graft survival, cold ischemia time, and the transplantation of highly se

48 and acute rejection; and donor age and race, cold ischemia time, and year of transplant.

49 Bilirubin and cold ischemia time are crucial for graft outcome post-LT

50 n those retrieved from cadaver donors, where cold ischemia times are significantly longer.

51 age Liver Disease score, and longer warm and cold ischemia times (C statistic, 0.75).

52 dictors, whereas donor age, gender and race, cold ischemia time, cadaveric versus living donor, delay

53 ), but this risk was limited to kidneys with cold ischemia time (CIT) >12 hours.

54 001), non-AA donor (HR 1.66, P < 0.001), and cold ischemia time (CIT) (HR 1.03 per hour >8 hours, P =

55 0.001) and kidneys with longer than 30 hr of cold ischemia time (CIT) (OR, 0.95; per 5% increment; 95

56 Prolonged cold ischemia time (CIT) affected BT rate significantly

57 Cadaveric kidneys experiencing longer cold ischemia time (CIT) are associated with higher leve

58 We used cold ischemia time (CIT) as an instrument to test the hy

59 Cumulative recurrence curves according to cold ischemia time (CIT) at 2-hour intervals and warm is

60 Prolonged cold ischemia time (CIT) is associated with a significan

61 ptimizing "modifiable risk factors," such as cold ischemia time (CIT) recipient warm ischemia time (W

62 The effect of this policy on cold ischemia time (CIT), delayed graft function (DGF),

63 covariates in both groups, while donor race, cold ischemia time (CIT), female to male transplants, an

64 Imported pancreata accumulate cold ischemia time (CIT), limiting utilization and worse

65 estigated in addition to causes of prolonged cold ischemia time (CIT).

66 or age, donor warm ischemia time (DWIT), and cold ischemia time (CIT).

67 percentage of transplanted ECD kidneys with cold ischemia times (CIT) <12 hr increased significantly

68 Concerns remain over prolonged cold ischemia times (CIT) associated with shipping kidne

69 on for short (3 hr; control) or long (18 hr) cold ischemia times (CIT).

70 ction criteria and the requirement for short cold-ischemia time (CIT).

71 phenomena, such as donor death and possibly cold ischemia time, contributed to differences in comple

72 were used to measure the relationships among cold ischemia time, delayed graft function, acute reject

73 ntibody more than 0%, cytomegalovirus D+/R-, cold ischemia time, delayed graft function, induction wi

74 Primary outcomes were discard, cold-ischemia time, delayed graft function, and 1-year g

75 ansplantation model grafts subjected to long cold ischemia time developed severe TV with intimal hype

76 erences, including donor brain death, longer cold ischemia time, diabetogenic immunosuppression, and

77 No significant differences in donor age, cold ischemia time, digestion time, or weight of the pan

78 e, panel-reactive antibody level, HLA match, cold ischemia time, donor age, and expanded criteria don

79 Cold ischemia times, donor age, and preoperative eGFR fo

80 Cadaveric transplants, prolonged cold ischemia time, elevated panel reactive antibody, an

81 ), expanded criteria donor kidney (15%), and cold ischemia time exceeding 24 hr (27%).

82 l operating room time (207 vs. 200 min.), or cold ischemia time (excluding pancreas).

83 The mean cold ischemia time for both groups was 11 +/-3 hr.

84 in start of surgery (25 vs. 77 min), shorter cold ischemia time for recovered pancreases (355 vs. 630

85 years (range, 1.0-50.0 years), and the mean cold ischemia time for the cadaveric kidneys was 27.0+/-

86 this group was significantly longer than the cold ischemia time for those without HAT (11.7 +/- 3.94

87 with donor body mass index >30 and pancreas cold ischemia time greater than 12 hr.

88 Recipients of kidneys with cold ischemia time greater than 24 hr also had a higher

89 For CAD kidney recipients, organ cold ischemia time greater than 24 hr increased the risk

90 tigen (HLA) mismatches, increased donor age, cold ischemia time greater than 24 hr, African American

91 xplant, donor age greater than 55 years, and cold ischemia time greater than 550 minutes were signifi

92 ican race, Kidney Donor Profile Index > 50%, cold ischemia time > 24 hours) and low-risk (not having

93 HTLV reactive, donation after cardiac death, cold ischemia time >12 hours, ICU stay >5 days, 3 or mor

94 DGF was associated with cold ischemia time >24 hr (P = 0.0003) and Rej (P = 0.06

95 s: donor age >55 yr, non-heartbeating donor, cold ischemia time >36 h, and donor hypertension or diab

96 (>55 years), donor hospital stay (>5 days), cold ischemia time (>10 hours), and warm ischemia time (

97 ithin 3 months posttransplant were prolonged cold ischemia time (>36 hours, odds ratio [OR]=3.38 vs.

98 ree of sensitization, retransplantation, and cold ischemia time; however, EBK recipients were somewha

99 icant correlation between apoptosis rate and cold ischemia time in CAD (r=0.86, P<0.001) renal allogr

100 10) that received a liver graft with a 16-hr cold ischemia time in Euro-Collins solution survived for

101 3+/-14.6 years (range: 0.7-50), and the mean cold ischemia time in the cadaveric cases was 26.5+/-8.8

102 Older recipient age and prolonged cold ischemia time increase the risk of graft failure.

103 matches, human leukocyte antigen antibodies, cold ischemia time, living donor, and preemptive transpl

104 he benefits of sustained euglycemia, shorter cold ischemia times, lower rates of sensitization, and e

105 There was no difference regarding cold ischemia time, model for end-stage liver disease sc

106 95% CI 1.23-2.02, P<0.001), and kidneys with cold ischemia time more than 24 hr (HR 1.31, 95% CI 1.04

107 95% CI 1.20-1.30, P=0.002) and kidneys with cold ischemia time more than 24 hr (HR 1.44, 95% CI 1.04

108 assessed using this technique after a median cold ischemia time of 13 h 19 min.

109 SSI: kidney from extended criteria donors, a cold ischemia time of more than 30 hr, time of surgical

110 es, including those of cadaveric grafts with cold ischemia times of as long as 41 hr.

111 The cold-ischemia time of the donor hand was 310 minutes.

112 was unassociated with 0Pre biopsy findings, cold ischemia time, or peak PT values.

113 There was no difference in donor age, cold ischemia time, or recipient United Network for Orga

114 groups in recipient demographics, donor age, cold ischemia time, or total number of doses of Thymoglo

115 d a reduction in use of donors with extended cold ischemia time (p = 0.04) and private pay recipients

116 Bilirubin (P=0.006) and cold ischemia time (P=0.002) were predictive of graft lo

117 ting for recipient age, sex, race, diabetes, cold ischemia time, panel cross-reactivity, pretransplan

118 ties for planning surgery and also decreases cold ischemia time, potentially translating into a highe

119 pancreas after kidney recipients, prolonged cold-ischemia time, prolonged donor hypotension, non-hea

120 A negative association to DeltaCP/GCr was cold ischemia time (r=-0.330, P<0.001).

121 , local origin of procurement team, pancreas cold ischemia time, recipient cerebrovascular disease.

122 vailability and thereby increase donor organ cold ischemia time that might then result in increased r

123 in the U.S. study had a significantly longer cold ischemia time (the time elapsed between procurement

124 r 120 min (30-min warm ischemia time, 90-min cold ischemia time), the second kidney was removed (NHBD

125 Assuming no change is cold ischemia time, the potential number of 0 CREG, 0 DR

126 ring of 0-MM kidneys significantly increased cold ischemia time, the risk of graft loss was significa

127 l reactive antibody, delayed graft function, cold ischemia time, time since start of dialysis, etiolo

128 enal grafts were transplanted with a shorter cold ischemia time to more poorly HLA-matched recipients

129 after adjusting for recipient and donor age, cold ischemia time, urine output, and Scr.

130 Within this range of cold ischemia time, UW and HTK demonstrate similar effic

131 Mean kidney cold ischemia time was 10 +/- 3 and 50 +/- 15 hours, for

132 The median cold ischemia time was 12 h 30 min (range 5 h 25 min-18

133 yte antigen (HLA) match was one; and average cold ischemia time was 12 hours.

134 In the marginal group, the cutoff value of cold ischemia time was 12.6 hr.

135 Mean cold ischemia time was 26.9+/-8.6 hr.

136 In cadaveric grafts, the mean cold ischemia time was 29.0 hours +/- 6.9 in those with

137 The mean cold ischemia time was 30.5+/-9.2 hr.

138 pancreatic excision was 34 minutes, whereas cold ischemia time was 6 hours and 40 minutes.

139 Mean cold ischemia time was 8.5 hr.

140 Cold ischemia time was a predictor of DGF independently

141 Cold ischemia time was longer in those with recurrent st

142 Cold ischemia time was not found to be an important fact

143 ets expressing either P-selectin or vWF, the cold ischemia time was significantly longer (885 +/- 123

144 experienced early acute rejection, the mean cold ischemia time was significantly longer than in allo

145 Cold ischemia time was strongly associated with DGF, wit

146 age difference, donor gender, donor type, or cold ischemia time were comparable.

147 percent) when the potential costs of longer cold ischemia time were considered.

148 gram, because the additional costs of longer cold ischemia time were greater than the advantages of o

149 Lactated Ringer's solution and 3-hr cold ischemia time were used for mechanistic investigati

150 Mean cold ischemia times were less than 20 hr.

151 n time (PT), retransplantation, and warm and cold ischemia times, were applied to the UNOS database.

152 milar among the groups with the exception of cold ischemia time, which was longer in the MP group com